Issiaka Soulama

Summary

Affiliation: Centre National de Recherche et de Formation sur le Paludisme
Country: Burkina Faso

Publications

  1. ncbi Plasmodium falciparum genotypes diversity in symptomatic malaria of children living in an urban and a rural setting in Burkina Faso
    Issiaka Soulama
    Centre National de Recherche et de Formation sur le Paludisme, 01 BP 2208 Ouagadougou 01, Burkina Faso
    Malar J 8:135. 2009
  2. ncbi Genetic diversity of polymorphic vaccine candidate antigens (apical membrane antigen-1, merozoite surface protein-3, and erythrocyte binding antigen-175) in Plasmodium falciparum isolates from western and central Africa
    Issiaka Soulama
    Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
    Am J Trop Med Hyg 84:276-84. 2011
  3. ncbi Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial
    Amadou T Konate
    Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
    PLoS ONE 6:e23391. 2011
  4. ncbi Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children
    Sodiomon B Sirima
    Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
    PLoS ONE 4:e7549. 2009
  5. ncbi Low-high season variation in Plasmodium falciparum erythrocyte binding antigen 175 (eba-175) allelic forms in malaria endemic area of Burkina Faso
    Issiaka Soulama
    Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
    Trop Med Int Health 15:51-9. 2010
  6. ncbi Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa
    Sodiomon B Sirima
    Centre National de Recherche et de Formation sur le Paludisme CNRFP, 01 BP 2208 Ouagadougou 01, Burkina Faso
    Vaccine 25:2723-32. 2007
  7. ncbi Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial
    Amadou T Konate
    Centre National de Recherche et de Formation sur Paludisme, Ouagadougou, Burkina Faso
    PLoS Med 8:e1000408. 2011
  8. ncbi Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa
    Issa Nebie
    CNRFP, 01 BP 2208, Ouagadougou 01, Burkina Faso
    Infect Immun 76:759-66. 2008

Collaborators

Detail Information

Publications8

  1. ncbi Plasmodium falciparum genotypes diversity in symptomatic malaria of children living in an urban and a rural setting in Burkina Faso
    Issiaka Soulama
    Centre National de Recherche et de Formation sur le Paludisme, 01 BP 2208 Ouagadougou 01, Burkina Faso
    Malar J 8:135. 2009
    ..The analysis of the Plasmodium falciparum genetic diversity in children with uncomplicated malaria, living in these two different areas, may help to understand the effect of urbanization on the distribution of P. falciparum genotypes...
  2. ncbi Genetic diversity of polymorphic vaccine candidate antigens (apical membrane antigen-1, merozoite surface protein-3, and erythrocyte binding antigen-175) in Plasmodium falciparum isolates from western and central Africa
    Issiaka Soulama
    Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
    Am J Trop Med Hyg 84:276-84. 2011
    ....
  3. ncbi Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial
    Amadou T Konate
    Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
    PLoS ONE 6:e23391. 2011
    ..We investigated whether intermittent preventive treatment of malaria in children (IPTc) was associated with an increase in the incidence of malaria after cessation of the intervention...
  4. ncbi Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children
    Sodiomon B Sirima
    Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
    PLoS ONE 4:e7549. 2009
    ..The aim of this study was to assess the safety and immunogenicity of this vaccine candidate in children aged 12-24 months living in malaria endemic area of Burkina Faso...
  5. ncbi Low-high season variation in Plasmodium falciparum erythrocyte binding antigen 175 (eba-175) allelic forms in malaria endemic area of Burkina Faso
    Issiaka Soulama
    Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
    Trop Med Int Health 15:51-9. 2010
    ..To assess the impact of seasonal variation on the distribution of the eba-175 allelic forms in the area where malaria transmission is markedly seasonal...
  6. ncbi Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa
    Sodiomon B Sirima
    Centre National de Recherche et de Formation sur le Paludisme CNRFP, 01 BP 2208 Ouagadougou 01, Burkina Faso
    Vaccine 25:2723-32. 2007
    ..We report here the first data on the safety, reactogenicity and immunogenicity of three doses of MSP3-LSP, adjuvanted with aluminium hydroxide, in healthy male adults living in a malaria endemic area...
  7. ncbi Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial
    Amadou T Konate
    Centre National de Recherche et de Formation sur Paludisme, Ouagadougou, Burkina Faso
    PLoS Med 8:e1000408. 2011
    ....
  8. ncbi Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa
    Issa Nebie
    CNRFP, 01 BP 2208, Ouagadougou 01, Burkina Faso
    Infect Immun 76:759-66. 2008
    ..Currently included in malaria vaccine formulations for clinical trials in humans, these blood-stage antigens, AMA1 and GLURP, offer good prospects for malaria vaccine development...